News
SEPN
19.24
+6.30%
1.14
Septerna Price Target Raised to $30.00/Share From $26.00 by HC Wainwright & Co.
Dow Jones · 15h ago
Septerna Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 15h ago
HC Wainwright & Co. Maintains Buy on Septerna, Raises Price Target to $30
Benzinga · 16h ago
Septerna price target raised to $30 from $26 at H.C. Wainwright
TipRanks · 17h ago
SEPTERNA, INC. <SEPN.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $30 FROM $26
Reuters · 17h ago
U.S. RESEARCH ROUNDUP-Cencora, Eagle Materials, Honeywell
Reuters · 21h ago
Analysts Offer Insights on Technology Companies: Lightpath Technologies (LPTH) and Septerna, Inc. (SEPN)
TipRanks · 1d ago
Septerna, Inc. GAAP EPS of $0.18, revenue of $21.5M
Seeking Alpha · 1d ago
Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 1d ago
Septerna reports Q3 EPS 18c, consensus 79c
TipRanks · 1d ago
*Septerna 3Q Rev $21.5M >SEPN
Dow Jones · 1d ago
*Septerna 3Q EPS 18c >SEPN
Dow Jones · 1d ago
*Septerna 3Q Net $8.17M >SEPN
Dow Jones · 1d ago
Septerna Reports Q3 Cash Position of $561.6 Million
Reuters · 1d ago
Press Release: Septerna Highlights Company -2-
Dow Jones · 1d ago
Press Release: Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Dow Jones · 1d ago
Weekly Report: what happened at SEPN last week (1103-1107)?
Weekly Report · 1d ago
SA Asks: Who's the next takeover target in the weight-loss drug space?
Seeking Alpha · 5d ago
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 5d ago
Septerna Inc. to Present at Guggenheim Healthcare Innovation Conference
Reuters · 11/03 13:00
More
Webull provides a variety of real-time SEPN stock news. You can receive the latest news about Septerna, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.